Abbott Navitor System Receives CE Mark for Expanded Surgical Risk Categories
August 29, 2025
August 29, 2025
WASHINGTON, Aug. 29 -- Abbott, Abbott Park, Illinois, has announced it has received a CE Mark in Europe for an expanded indication for its Navitor(TM) transcatheter aortic valve implantation (TAVI) system.
The company stated on August 29, 2025, that the system can now be used to treat patients with severe aortic stenosis who are at low or intermediate risk for open-heart surgery, in addition to the high-risk patients for whom it was already approved. This new approval significantly . . .
The company stated on August 29, 2025, that the system can now be used to treat patients with severe aortic stenosis who are at low or intermediate risk for open-heart surgery, in addition to the high-risk patients for whom it was already approved. This new approval significantly . . .